Review article: Nucleoside analogues for the treatment of chronic hepatitis B. (Q35987869)

11 August 2017

1 reference

title

Review article: Nucleoside analogues for the treatment of chronic hepatitis B. (English)

1 reference

11 August 2017

1 reference

1 reference

Younger HM

1

1 reference

11 August 2017

Bathgate AJ

series ordinal

2

1 reference

11 August 2017

Hayes PC

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Alimentary Pharmacology & Therapeutics

11 August 2017

published in

1 reference

11 August 2017

volume

20

1 reference

11 August 2017

issue

11-12

1 reference

11 August 2017

page(s)

1211-1230

1 reference

Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Nucleoside analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Famciclovir in chronic hepatitis B: results of a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Octreotide ameliorates the increase in collateral blood flow during postprandial hyperemia in portal hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Clinical trial of lamivudine in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2004.02211.X

10.1111/J.1365-2036.2004.02211.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference